Codexis, Inc.
$2.62
▲
4.6%
2026-04-21 05:58:00
www.codexis.com
NMS: CDXS
Explore Codexis, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$235.35 M
Current Price
$2.62
52W High / Low
$3.87 / $0.96
Stock P/E
—
Book Value
$0.56
Dividend Yield
—
ROCE
-31.3%
ROE
-74.88%
Face Value
—
EPS
$-0.5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
146
Beta
2.08
Debt / Equity
144.88
Current Ratio
3.82
Quick Ratio
3.75
Forward P/E
-10.18
Price / Sales
2.89
Enterprise Value
$198.55 M
EV / EBITDA
-6
EV / Revenue
2.82
Rating
Buy
Target Price
$6.58
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
| 2. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
| 3. | Greenwich LifeSciences, Inc. | $24.52 | — | $384.32 M | — | -631.87% | -5.43% | $34.1 / $7.78 | $0.16 |
| 4. | Olema Pharmaceuticals, Inc. | $16.58 | — | $1.47 B | — | -37.1% | -36.61% | $36.26 / $3.89 | $5.88 |
| 5. | Pulmatrix, Inc. | $1.34 | — | $4.91 M | — | -135.67% | -80.93% | $9.37 / $1.16 | $1.04 |
| 6. | Madrigal Pharmaceuticals, Inc. | $535 | — | $12.26 B | — | -31.61% | -42.49% | $615 / $265 | $26.39 |
| 7. | Moolec Science SA | $7.28 | — | $5.29 M | — | 11.2% | 344.24% | $157.05 / $3.07 | $0.7 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 38.91 M | 8.6 M | 15.33 M | 7.54 M | 21.46 M | — |
| Operating Profit | 13.97 M | -18.95 M | -12.86 M | -20.49 M | -7.34 M | — |
| Net Profit | 9.6 M | -19.61 M | -13.27 M | -20.69 M | -10.38 M | — |
| EPS in Rs | 0.11 | -0.22 | -0.15 | -0.23 | -0.11 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 70.39 M | 59.34 M | 70.14 M | 138.59 M |
| Operating Profit | -38.33 M | -58.35 M | -54.8 M | -31.71 M |
| Net Profit | -43.97 M | -65.28 M | -76.24 M | -33.59 M |
| EPS in Rs | -0.48 | -0.72 | -0.84 | -0.37 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 147.8 M | 149.01 M | 136.56 M | 250.39 M |
| Total Liabilities | 97.27 M | 82.08 M | 49.95 M | 105.6 M |
| Equity | 50.53 M | 66.93 M | 86.61 M | 144.8 M |
| Current Assets | 96.82 M | 98.77 M | 93.47 M | 162.89 M |
| Current Liabilities | 25.32 M | 23.65 M | 35.83 M | 49.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -19.38 M | -49.41 M | -52.64 M | 11.28 M |
| Investing CF | 23.5 M | -56.98 M | -4.86 M | -13.58 M |
| Financing CF | 27.93 M | 60.52 M | 8.17 M | -0.57 M |
| Free CF | -23.85 M | -53.72 M | -57.06 M | 2.98 M |
| Capex | -4.47 M | -4.3 M | -4.42 M | -8.31 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -15.39% | -49.39% | — | — |
| Earnings Growth % | 14.38% | -126.96% | — | — |
| Profit Margin % | -109.99% | -108.69% | -24.24% | — |
| Operating Margin % | -98.33% | -78.13% | -22.88% | — |
| Gross Margin % | 72.55% | 81.74% | 72.56% | — |
| EBITDA Margin % | -84.09% | -83.23% | -18.99% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.